Background: Mortality in people living with HIV/AIDS is one of measures to the success of its treatment. Study related to their deaths seen from gender is still very limited. Objective: The aim of this study was to determine the incidence rate of mortality between men and women living with HIV/AIDS and receiving antiretroviral therapy. Results: A total of 1204 HIV/AIDS-infected patients data was included. The incidence of total mortality rates was 27.7 per 1000 person-years. Based on gender, the mortality in men (35 per 1000 person-years) was higher than women (14 per 1000 person-years) with the incidence rate ratio (IRR) of 2.39 (p 0.01). Fifty percent of cases of mortality occured at 0.15 years of observation. The median time of mortality in men was 0.14 years (1.7 months) and in women was 0.15 years (1.8 months). The poor clinical condition was seen from a body weight <50 kg, which increased the risk of death with aOR 3.85 (p 0.01 CI 2.40-6.16). Nevirapine increased the risk of mortality (aOR 2.18; p 0.01; CI 1.18-4.03). and CD4 cell counts of ≤ 200 cells / mm3 reduced the risk of death by 69% (AOR 0.31; p 0.01; CI 0.18-0.53).
INTRODUCTION
HIV / AIDS epidemic is still a global issue that needs special attention. Various programs are developed to achieve the goal of reducing the risk of transmission. The four pillars of HIV/AIDS prevention in Indonesia that lead to a paradigm zero new infection, zero AIDS-related death and zero discrimination include prevention, care, support and treatment, mitigation of impacts, and preparation of a conducive environment (MOH, 2010 (MOH, , 2011a . Indicators to measure the success of antiretroviral (ARV) therapy programs in people living with HIV are the mortality rate and loss to follow-up (LTFU) rate. Both measures are very influential in the Dewi, P.D.P.K., et al. Belitung Nursing Journal. 2018 December; 4(6):559-565 Received: 4 September 2018 | Revised: 26 September 2018 | Accepted: 9 October 2018 https://belitungraya.org/BRP/index.php/bnj/index continuity of therapy. Bali was the seventh highest province in Indonesia for the mortality of people living with HIV/AIDS (PLHA) in ARV therapy. Although it is still below the national mortality percentage (18.04%), but still far from the target of zero AIDS-related death (ASEAN Nations, 2011) .
Common clinical conditions associated with the incidence of mortality in PLHA are weight, CD4 cell count, clinical stage and functional status. Thus, ARV therapy requires adherence to therapy so that patient compliance must always be monitored and evaluated regularly at each visit. Failure of ARV therapy is often caused by non-adherence patients taking ARV (Lamb, El-Sadr, Geng, & Nash, 2012; MOH, 2011a; WHO, 2013) . And gender is one of variables that greatly determines the pattern of adherence in ARV therapy. Risk of mortality in men tends to be higher (RR 1.19, aSHR 1.7) compared to women (Hawkins et al., 2011; Mugisha et al., 2014) . Men have different adherence than women, and they still have worse treatment. While women have a greater position in matters related to depression, stress, stigmatization, and social roles related to gender (Applebaum, Richardson, Brady, Brief, & Keane, 2009 ). In addition, social and cultural stigma is more likely with men and related to the prevention, awareness, and treatment of diseases (Mitra & Sarkar, 2011) . However, the results of gender studies related to ARV therapy are still inconsistent. Studies on gender analysis in the case of mortality in PLHA with ARV therapy in Indonesia, especially in Bali Province are still limited. The aim of this study was to describe the incidence rates of mortality based on gender analysis.
METHODS

Study design
This was a retrospective study with secondary data of HIV/AIDS-infected obtain the incidence rate of death rate per 100 people according to a year and adjusted odds ratio, in addition to the median time of mortality until the end of the observation year. Bivariate analysis with p-value and survival rate was used to see the significance of the differences between the respective groups. The value of the crude Odds Ratio (cOR), p specific, and p of OR crude from each independent variable to mortality were performed using logistic regression with a 95% confidence level. The parm test was used when the nominal independent variable was for three or more categories, and we used a test for the trends when the ordinal data or intervals were in two or more categories. Logistic Regression with backward model was used for multivariate analysis. The insignificant variables were removed from the model until the final model was obtained.
RESULTS
The results of the study from 1204 data on PLHA patients who met the inclusion criteria showed that the percentage of death cases was 9.30%. The proportion of mortality in men was 79.46% and females were 20.54%. The incidence rates of death Table 2 shows that the incidence rates of mortality in men were 35 per 1000 person-years, which is higher than women with 14 per 1000 personyears (See also Figure 2) . The results of multivariate analysis in Table 3 also showed that three variables related to death. Weight <50 kg was 3.85 times increasing death (Adj OR 3.85 95% CI 2.40-6.16 p=0.01). ARV Therapy in NNRTI and Nevirapine were 2.18 times increasing death (Adj OR 2.18 95% CI 1.18-4.03 p=0.01). CD4 with level < 200 cell / mm 3 decreased death until 64 % (Adj OR 0.31 95% CI 0.18-0.53 p=0.01).
Figure 2 Kaplan Meier Death of PLHAs based on Gender
DISCUSSION
The incidence rates of mortality in men were 35 per 1000 person-years while in women were 14 per 1000 person-years. This result is in line with several studies, which found that the incidence of mortality rates in men was higher than in women (Hawkins et al., 2011; Taylor-Smith, Tweya, Harries, Schoutene, & Jahn, 2010; Weigel et al., 2012) . Nonadherence to treatment contributes to death by up to 50% (Brinkhof, Pujades-Rodriguez, & Egger, 2009; Wubshet, Berhane, Worku, & Kebede, 2013) . The incidence rate ratio (IRR) was 2.39 (p 0.01), which showed that the risk of mortality in men was 2.39 times that of women.
The success of ARV therapy requires adherence to therapy for HIV/AIDS patients, so the adherence of a patient must be monitored and evaluated regularly at each visit. Failure of ARV therapy is often caused by non-adherence to patients taking ARV (Lamb et al., 2012; MOH, 2011a; WHO, 2013) . ARV therapy requires maximum adherence.
Men have a tendency to behave worse in adherence to treatment. They tend to come to health services with poor clinical conditions so that the risk of death is greater (Brinkhof et al., 2009; Brinkhof et al., 2010; Gabillard et al., 2013; Weigel et al., 2012; Wilkinson, SkordisWorrall, Ajose, & Ford, 2015) .
Multivariate analysis with backward model shows three characteristics that have been statistically significant to increase the risk of death. Weight less than 50 kg increases the risk of death by 3.85 times. Body weight was the clinical indicator of the quality of life of PLHA. Body weight is a reference commonly used to assess nutritional status. People with HIV who start therapy weighing less than 45 kg are more at risk of death. Weight loss > 10% is a common symptom experienced when infected with HIV (Dalal et al., 2008) . On the contrary, every one kilogram increased in body weight reduced the risk of death in PLHA who experienced LTFU by 6% (HR 0.94; (Kusuma Dewi & Widiarta, 2018) .
ARV regimen consisted of nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase (NNRTI). Nevirapine (NVP) increases the risk of death by 2.18 times. The antiretroviral regimen related to drug characteristics and side effects and the easy of access to ARVs impact on the compliance of PLHA (Ford et al., 2013; MOH, 2011b ). NVP has a greater level of toxicity in the general population, where the toxic effects reach 1.5 times (OR 1.5, 95% CI 0.9-2.3) (Ford et al., 2013) . Nevirapine also increases the risk of death in PLHA who experienced LTFU by 3.92 (Kusuma Dewi & Widiarta, 2018) . Severe side effects certainly contributed to the case of the death of PLHA. When starting therapy with a higher CD4 in 350 cell / mm 3 can reduce the effect of toxicity on PLHAs (Clouse et al., 2013; MOH, 2011a) . The rate of CD4 becomes a benchmark for the health status of PLHAs and immunological failure indicators in ARV therapy. CD4 examination completes clinical examinations that can guide in determining the time to start treatment prophylaxis against opportunistic infections (OI) and ARV therapy before the disease continues to worsen. CD4 levels ≤ 200 cells / mm 3 reduced the risk of death by 69% with aOR 0.31 (p 0.01 CI 0.18-0.53). This condition is inversely proportional to research, which states that a low CD4 cell count can increase the risk of death (Clouse et al., 2013; Gabillard et al., 2013) .
The limitation in this study is that there are still gaps in CD4 variables that cannot yet be explained in detail so that further research is needed to link the CD4 count with the risk of death by looking at the magnitude of the effect. Qualitative research is also needed to look at the treatment and loss-to-follow-up by gender-based.
CONCLUSION
The incidence of mortality in men was 2.39 times greater than women and poor clinical conditions tend to worsen the health condition of PLHA so the risk of death was even greater. The incidence rate of death rates in men was 35 per 1000 PY while in women14 per 1000 PY. Poor clinical conditions with a body weight below 50 kg increase the risk of death by 3.85 times. The level of nevirapine (NVP) NNRTI toxicity increases the risk of death by 2.18 times. CD4 cell counts less than 200 cells / mm 3 reduce the risk of death by 69%. It is better to evaluate the success of ARV therapy considering the study and differences in needs between women and men. Further research needs to be carried out on the adherence of treatment and loss to follow-up (LTFU) genderbased events.
